Primary drug resistance in a region with high burden of tuberculosis. A critical problem

Salud Publica de Mexico

Volumn 57, Issue 2, 2015, Pages 177-179

  Villa Rosas, Cecilia ^a,b   Laniado Laborín, Rafael ^a,b   Oceguera Palao, Lorena ^a,b  

^a Instituto de Servicios de Salud Pública de Baja California   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE BAJA CALIFORNIA   (Mexico)

Author keywords

Isoniazid; Resistance amplification; Rifampin; Treatment outcome

Indexed keywords

TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; COMORBIDITY; DRUG EFFECTS; ENDEMIC DISEASE; FEMALE; HIV INFECTIONS; HUMAN; ISOLATION AND PURIFICATION; MALE; MEXICO; MICROBIOLOGY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; ANTITUBERCULAR AGENTS; COMORBIDITY; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENDEMIC DISEASES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEXICO; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84928620036     PISSN: 00363634     EISSN: 16067916     Source Type: Journal    
DOI: 10.21149/spm.v57i2.7414     Document Type: Article

References (10)

1. Yee DP, Menzies D, Brassard P. Clinical outcomes of pyrazinamidemonoresistant Mycobacterium tuberculosis in Quebec. Int J Tuberc Lung Dis 2012;16:604-609.
2. Gegia M, Cohen T, Kalandadze I, Vashakidze L, Furin J. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. Int J Tuberc Lung Dis 2012;16:812-816.
3. Dantes R, Metcalfe J, Kim E, Kato-Maeda M, Hopewell PC, Kawamura M, et al. Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. PLoS ONE 2012;7:e37956. doi:10.1371/journal.pone.0037956.
4. Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, et al. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis. Clin Infect Dis 2004;39:1321-1328.
5. Instituto Nacional de Estadística, Geografía e Informática. Número de habitantes [online monograph]. México: Inegi, 2014. [accessed on 2014 December 17]. Aviable at: http://cuentame.inegi.org.mx/monografias/informacion/bc/poblacion/
6. World Health Organization. Treatment of tuberculosis: guidelines-4th ed WHO/HTM/TB/2009.420. Geneva: WHO, 2009: 420.
7. Menzies D, Benedetti A, Paydar A, Royce S, Pai M, Burman W, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med 2009;6:e1000150. doi:10.1371/journal. pmed.1000150.
8. World Health Organization. Guidelines for the programmatic management of drug-resistant TB: emergency update 2008. Geneva, Switzerland:WHO, 2008.
9. Curry International Tuberculosis Center and California Department of Public Health. Drug-resistant tuberculosis: a survival guide for clinicians. 2nd ed. San Francisco, California: University of California, 2011:33.
10. Grzybowski S, Enarson D. The fate of cases of pulmonary tuberculosis under various treatment programmes. Bull Int Union Tuberc Lung Dis 1978;53:70-75.